BioStock: Chairman envisions continued success for Aqilion

Aqilion, led by CEO Sarah Fredriksson, focuses on developing new treatments for diseases caused by chronic inflammation. In February, the company announced a major licensing deal and strategic collaboration with Merck. The deal, worth upwards of EUR 950 million, is aimed at the discovery, development and commercialisation of TAK1 protein inhibitors. The company’s Chairman, Bertil Lindmark, visited the BioStock Studio to talk about his vision for the company and ambitions for continued success.

Watch the interview with Aqilion’s Chairman Bertil Lindmark at biostock.se

Chairman envisions continued success for Aqilion - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/